Blood pressure control in a diabetic population assessed by computer review

Journal of Human Hypertension

Volumn 20, Issue 7, 2006, Pages 540-542

  Swislocki, Arthur ^a,b   Noth, R H ^a,b   Volpp, B ^a   Meier, J ^a   Siegel, D ^a,b  

^a VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; POTASSIUM SPARING DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL PROTOCOL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; HEALTH CARE SYSTEM; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MEDICAL RECORD; PATIENT COMPLIANCE; POPULATION RESEARCH; PRESCRIPTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS; HUMANS; HYPERTENSION; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED;

EID: 33745284288     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001987     Document Type: Article

References (12)

1. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762.
2. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
3. American Diabetes Association. Treatment of hypertension in adults with diabetes (Position Statement). Diabetes Care 2003; 26(Suppl 1): S80-S82.
4. Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339: 1957-1963.
5. Swislocki ALM, Lin K, Cogburn D, Fann FY, Khuu DT, Noth RH. Postmarketing analysis of lovastatin use in the VA Northern California System of Clinics: A retrospective, computer-based study. Am J Man Care 1997; 3: 1537-1545.
6. Swislocki ALM, Khuu Q, Liao E, Wu E, Beza F, Lopez J et al. Safety and efficacy of metformin in a restricted formulary. Am J Man Care 1999; 5: 62-68.
7. Snedecor GW, Cochran WG. Statistical Methods, 8th edn. Iowa State University Press: Ames, IA, 1989.
8. Swislocki ALM, Siegel D. Renal effects of angiotensin-converting enzyme inhibitors that result in cost savings and improved patient outcomes. Am J Man Care 2001; 7: 283-295.
9. Perry HM, Bingham S, Horney A, Rutan G, Sambhi M, Carmody S, et al., for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Antihypertensive efficacy of treatment regimens used in Veterans Administration Hypertension Clinics. Hypertension 1998; 31: 771-779.
10. Joffres MR, Hamet P, MacLean DR, L'italien GJ, Fodor G. Distribution of blood pressure and hypertension in Canada and the United States. Am J Hypertens 2001; 14: 1099-1105.
11. Chamontin B, Lang T, Vaisse B, Nicodeme R, Antoine M-P, Lazorthes M-L et al. Hypertension arterielle et facteurs de risque cardiovasculaires associes chez les diabetiques. Arch Mal Coeur 2001; 94: 869-873.
12. Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000; 23: 754-758.